Cancer screening metrics: effective evaluation to balance benefits and harms

A new study led by researchers at the International Agency for Research on Cancer (IARC) and published today in the Journal of the American Medical Association assesses whether the incidence of late-stage cancer could be a suitable alternative end-point in randomized clinical trials of cancer screening, in place of cancer-specific mortality, the gold-standard end-point.

Feng X, Zahed H, Onwuka J, Callister ME, Johansson M, Etzioni R, et al.
Cancer stage compared with mortality as end points in randomized clinical trials of cancer screening: a systematic review and meta-analysis
JAMA. Published online 7 April 2024
https://doi.org/10.1001/jama.2024.5814

Read the article

Read IARC Press Release 348

Read the Q&A